B−80/100
Graded #7Editorial review
Hims & Hers
Mass-market app-first program with nationwide reach and consumer-grade polish.
Visit Hims & Hers ↗Editorial review — no commercial relationship.
- Semaglutide
- $199/mo
- Tirzepatide
- Not disclosed
- Coverage
- All 50 states
- Brand-name
- Compounded only
Factor breakdown
Each of the six graded dimensions. See the methodology.
Cost value82/100
Dose & formulation78/100
Clinical oversight82/100
Labs & monitoring80/100
Fulfillment84/100
Contract terms80/100
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Bottom line — Grade B−
Best for: People who want a familiar, app-driven consumer brand.
Pricing/verification reflect Hims & Hers's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Hims & Hers's site. Not medical advice; see our disclosure.